Novotech Partners with South Korea’s Pusan National University Hospital

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

June 18, 2020

Novotech, the leading Asia-Pacific biotech specialist CRO, has partnered with South Korea’s world-class Pusan National University Hospital (PNUH).

Novotech notes the Partnership is designed to further support Novotech’s biotech clients run their clinical trials in the region.

Dr. Jeong Zoo Lee, the President of PNUH, said: “The PNUH site team and Novotech have worked together on a number of studies already. We have progressed to a formal agreement to support Novotech’s biotech clients across all clinical research and patient recruitment areas.

“We are pleased to partner with a regional CRO leader with such an outstanding reputation internationally,” said Dr. Lee.

Dr. Yooni Kim, Executive Director, Asia Operations said: “Novotech was very pleased to establish a Partnership with PNUH, which has completed more than 340 clinical trials and is ranked 7th in terms of number of clinical trials in South Korea *GlobalData.

“The PNUH site offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea’s supportive rapid start-up environment. The main therapeutic areas at PNUH have been oncology, infectious disease, cardiovascular and gastrointestinal,” said Dr. Kim.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.